BIOHAVEN LTD
BHVNNYSETrading Snapshot
- Day Range
- $14.31 โ $14.51
- 52-Week Range
- $7.48 โ $18.57
- Volume
- $1.88B
- Avg Volume
- $1.63B
- Shares Outstanding
- 150.6M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $153M
- Last Q Revenue
- $36M
- P/E Ratio
- -3.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.90
- Dividend Yield
- 0.00%
Why Investors Own BHVN
- โHigh-growth profile โ revenue up +55.8% YoY with expanding US Equity exposure.
- โHealthy economics โ 35% gross margin and 10% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIOHAVEN LTD
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $18 to $19.
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.
Biohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate
Biohaven (NYSE:BHVN) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.73) by 6.85 percent. This is a 52.15 percent increase over losses of $(1.63) per share from the same
Biohaven And Yale University Announce Federal Jury Verdict In Their Favor In Trade Secret Misappropriation And Breach Of Contract Litigation Against Avilar Therapeutics And RA Capital
The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital separately breached its
Stay Bullish Despite The Rough Week: Aerospace, Finance, Biotech, And AI
Stay bullish amid market volatility with insights on semiconductors (Micron, Nvidia), aerospace/defense, biotech & AIรขยยplus valuation and 2026 outlook.
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.